These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 14724308)

  • 61. What have We learned from ESPRIT? What will we learn from TARGET?
    Ferguson JJ
    J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
    [No Abstract]   [Full Text] [Related]  

  • 62. Antiplatelet agents in cardiology: the choice of therapy.
    Steinhubl SR
    Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S3-8. PubMed ID: 10966004
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antiplatelet agents in stroke prevention. combination therapy: present and future.
    Weksler BB
    Cerebrovasc Dis; 2000; 10 Suppl 5():41-8. PubMed ID: 11096182
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
    Mukherjee D; Chew DP; Robbins M; Yadav JS; Raymond RE; Moliterno DJ
    J Thromb Thrombolysis; 2001 Apr; 11(2):151-4. PubMed ID: 11406730
    [TBL] [Abstract][Full Text] [Related]  

  • 65. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
    Talley JD
    J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
    [No Abstract]   [Full Text] [Related]  

  • 66. Post-procedural patient management: prevention and management of bleeding complications.
    Aguirre F
    J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
    [No Abstract]   [Full Text] [Related]  

  • 67. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 68. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 69. Letter by Lin et al regarding article, "Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention".
    Lin GM; Chu KM; Han CL
    Circulation; 2010 Feb; 121(7):e43; author reply e44-5. PubMed ID: 20177003
    [No Abstract]   [Full Text] [Related]  

  • 70. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
    Steinhubl SR; Moliterno DJ
    Heart Vessels; 1997; Suppl 12():148-55. PubMed ID: 9476567
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 72. Optimal treatment of acute coronary syndromes--an evolving strategy.
    Boden WE; McKay RG
    N Engl J Med; 2001 Jun; 344(25):1939-42. PubMed ID: 11419433
    [No Abstract]   [Full Text] [Related]  

  • 73. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 74. [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
    Niessner A; Niessner H; Huber K
    Herz; 2001 Apr; 26 Suppl 1():36-41. PubMed ID: 11349625
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
    Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
    Tcheng JE; Campbell ME
    J Am Coll Cardiol; 2003 Oct; 42(7):1196-8. PubMed ID: 14522479
    [No Abstract]   [Full Text] [Related]  

  • 77. [Coronary syndromes in the elderly].
    Bounhoure JP; Carrié D; Puel J
    Bull Acad Natl Med; 2006; 190(4-5):807-16; discussion 816, 873-6. PubMed ID: 17195608
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
    Campbell P
    N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228
    [No Abstract]   [Full Text] [Related]  

  • 79. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
    Madan M; Berkowitz SD; Christie DJ; Jennings LK; Smit AC; Sigmon KN; Glazer S; Tcheng JE
    Am Heart J; 2001 Feb; 141(2):226-33. PubMed ID: 11174336
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
    Boden WE; Hoekstra J; Miller CD
    Am J Emerg Med; 2008 Feb; 26(2):212-20. PubMed ID: 18272105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.